Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 19/20 | 0.40 |
| ▸ | GCG | P01275 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | SCN7A | Q01118 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23332730 | 0.91 | SCN9A (0.41) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL23332736 | 0.87 | SCN9A (0.40) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL23332750 | 0.87 | SCN9A (0.40) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL23332923 | 0.87 | SCN9A (0.40) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL23333260 | 0.86 | SCN9A (0.49) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL23332914 | 0.86 | SCN9A (0.44) | SCN9ASCN10A | |
| SCHEMBL23332841 | 0.84 | SCN9A (0.46) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL23332896 | 0.82 | SCN9A (0.43) | SCN9ASCN10A | |
| SCHEMBL23294672 | 0.81 | ATF4 (0.51) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL21389925 | 0.81 | ATF4 (0.51) | SCN9ASCN10ASCN7AKCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | SCN9A 3136/4885GCG 4251/4885SCN10A 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.